ABCG2 and neoplasm: This senescence-associated stemness enhances the tumour’s aggressiveness and risk of recurrence, as demonstrated in liver cancer studies where EpCAM+/CD133+ stem cells exhibit increased resistance to doxorubicin due to elevated ABCG2 expression (Zhang et al., 2020; Karabicici et al., 2021).